Add Yahoo as a preferred source to see more of our stories on Google. By Deena Beasley (Reuters) - Express Scripts Holding Co on Tuesday announced a new drug reimbursement list with lower U.S. prices ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

On Tuesday, Express Scripts released its annual list of formulary exclusions, which included several drugs to treat rare diseases like hemophilia, HIV and hepatitis C. Many of these products, ...

(Reuters) - Express Scripts Holding Co on Tuesday announced a new drug reimbursement list with lower U.S. prices for brand-name medications, as a way to encourage drugmakers to move away from paying ...

The digital health market continues to grow exponentially with apps that promote fitness, wellness and the prevention of chronic conditions as well as telehealth solutions and remote monitoring tools.

Another major pharmacy benefit manager is adding Humira biosimilars to its formulary beginning next year. Express Scripts, which is part of Cigna's Evernorth subsidiary, said Monday that it will add ...

Pharmacy benefit manager Express Scripts is launching a digital health formulary next year: a list of digital health tools, including smartphone apps and software-enabled medical devices, to help ...

Express Scripts said Wednesday it's rolling out a new formulary aimed at giving will employers and health plans a way to cover lower priced products and reduce reliance on rebates for brand-name ...

During a yearslong examination of drug prices, there’s been no shortage of criticism for growing list prices, and in recent months, some companies have heard the talk and lowered their prices. Now, ...

Express Scripts will include Cyltezo and both Sandoz products (Hyrimoz and unbranded adalimumab-adaz) – inflammatory disease biosimilars with competitive net costs – as preferred products on the ...